Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Cannabidiol (Dravet syndrome) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-119
Last updated

Report documents

  1. Extract of dossier assessment

    Cannabidiol (Dravet-Syndrom) - Nutzenbewertung gemäß § 35a SGB V

    published on
    Document type
    PDF document, 350 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-119_en
    Download file : Extract of dossier assessment (PDF document, 350 kB, EN, not accessible)

  2. Dossier assessment

    Cannabidiol (Dravet syndrome) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 571 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-119
    Download file : Dossier assessment (PDF document, 571 kB, DE, not accessible)

Dossier assessment

Indication:

Adjunctive therapy in patients 2 years of age and older with seizures associated with Dravet syndrome

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A23-119
Commission
Commission awarded on 04.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-119_en

Connected Projects

  1. Dossier assessment

    Cannabidiol (seizures in tuberous sclerosis complex) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G21-17
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Cannabidiol for the treatment of Dravet syndrome in patients from the age of 2 years - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G20-24
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Cannabidiol for the treatment of Lennox-Gastaut syndrome in patients from the age of 2 years - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G20-25
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Cannabidiol (Lennox-Gastaut syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G19-18
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Cannabidiol (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G19-17
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Cannabidiol (tuberous sclerosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-121
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Cannabidiol (Lennox Gastaut syndrome) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-120
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page